Obstetrical and medical outcomes following GLP-1 receptor agonist exposure in pregnancy: a case series Authors: Karen Wong, Houda Al-Amri, Ana Werlang Published: 2026 ABSTRACT AbstractThe use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has increased over the past several years. The resulting improved blood sugar control and optimized body weight ultimately improve fertility. Thus, it is increasingly common to have individuals inadvertently becoming pregnant while using GLP-1 RAs. This case series describes outcomes following the inadvertent use of GLP-1 RAs in the first trimester of pregnancy, including the incidence of major malformations, maternal glucose control and gestational weight gain.This case series included individuals receiving obstetric care at a tertiary perinatal center who had exposure to a GLP-1 RA between 2 months preconception to pregnancy conclusion for any indication or duration. Electronic medical records of participants were reviewed for fetal, obstetrical, maternal, and neonatal outcomes.There were 16 patients in the series. All had spontaneous and unplanned conception of singleton pregnancies while using subcutaneous semaglutide and continued administration during a part of the first trimester. All included patients were overweight or obese.No individual lost weight in pregnancy. No major fetal anomalies were identified. Following discontinuation of semaglutide, diabetes control required both metformin and insulin for most patients. There was one instance of iatrogenic preterm birth at 35 weeks for preeclampsia. The rate of preeclampsia was 18.8%. Given the high rate of obesity, there was a lower-than-expected rate of excessive gestational weight gain (37.5%).Further studies on the safety and possible benefits of GLP-1 RAs in pregnancy are required.Keywords: Pregnancy, Gestational weight gain, Diabetes mellitus, Obesity, glucagon-like peptide-1 receptor agonist Introduction The use of glucagon-like peptide 1-receptor agonists (GLP-1 RAs) for management of type 2 diabetes mellitus (T2DM), polyendocine metabolic ovarian syndrome (PMOS), and weight loss has increased over the past several years. Improved blood sugar control and optimized body weight ultimately improve fertility. Thus, it is increasingly common to have individuals inadvertently becoming pregnant while using GLP-1 RAs. With increasing exposure, safety data for these medications in pregnancy is accruing. No published studies have reported a human teratogenic risk associated with GLP-1 RA use [1], [2], [3], [4], [5], [6]. Indeed, direct teratogenic effects are not anticipated due to the high molecular weight of these molecules, which are therefore not expected to cross the placenta [6]. However, there may be other sequelae related to GLP-1 RA use in pregnancy. A higher risk of excessive gestational weight gain (GWG) has been described for obese or diabetic individuals exposed to but discontinuing GLP-1 RAs in pregnancy [7]. Another study questioned an increased risk of preterm birth associated with GLP-1 RAs, although this risk was attenuated relative to individuals using insulin [1]. This case series describes outcomes following the inadvertent use of GLP-1 RAs in the first trimester of pregnancy, including the incidence of major malformations, maternal glucose control and GWG. Case Series This case series included individuals receiving obstetric care at a tertiary perinatal center between August 1, 2023 and October 31, 2024. Patients were included if they had exposure to a GLP-1 RA between 2 months preconception to pregnancy conclusion for any indication or duration. The time frame was selected to reflect recent practices in GLP-1 RA prescribing and use, and the sample size was one of convenience. Electronic medical records of participants were reviewed for fetal, obstetrical, maternal, and neonatal outcomes. Society of Obstetrician and Gynaecologists of Canada guidelines were used in the definition of preeclampsia [8], fetal growth restriction [9], and polyhydramnios [10]. Pre-existing diabetes was managed according to the guidelines of Diabetes Canada [11]. Institute of Medicine definitions were used in the classification of GWG appropriateness [12]. GWG was calculated as patient-reported pre-pregnancy weight, subtracted from last measured weight in pregnancy. As a retrospective case series using previously collected clinical data, informed consent was not sought or obtained. Institutional research ethics board approval was obtained (#20240722-01H). Descriptive statistics are used to describe maternal demographics and outcomes. Results There were 1016 new patients seen in the clinic during this time, of whom 16 were exposed to GLP-1 RAs and included in this study. Table 1 reports patient characteristics. The only GLP-1 RA used was subcutaneous semaglutide. Indications for use were T2DM (94%) and obesity (6%). Table 1Characteristics of 16 patients exposed to semaglutide in the periconceptual period or first trimester.Baseline characteristicsExposed to semaglutide (n = 16)Maternal age (years), mean ± SD34.6 ± 5.7Primiparous, n (%)6 (37.5%)BMI pre-pregnancy (kg/m2), mean ± SD35.0 ± 6.7 BMI 25–29.9, n (%)4 (25%) BMI 30–39.9, n (%)7 (43.8%) BMI ≥ 40.0, n (%)5 (31.3%)Semaglutide dose (mg/week), median ± IQR1.0 ± 0.0GA at discontinuation (days), median ± IQR35.0 ± 7Chronic hypertension, n (%)3 (18.8%)History of HDP, n (%)1 (6.3%)History of preterm delivery, n (%)1 (6.3%)History of congenital anomaly, n (%)1 (6.3%)BMI: body mass index.GA: gestational age.HDP: hypertensive disorder of pregnancy. Characteristics of 16 patients exposed to semaglutide in the periconceptual period or first trimester. BMI: body mass index. GA: gestational age. HDP: hypertensive disorder of pregnancy. All patients had spontaneous and unplanned conception of singleton pregnancies while using subcutaneous semaglutide and continued administration during a part of the first trimester. The latest exposure to semaglutide recorded was at 8 weeks 2 days. Table 2 describes obstetrical and neonatal outcomes. All included patients were overweight. No individual lost weight in pregnancy. Table 2Maternal and neonatal outcomes.OutcomePregnancies exposed to semaglutide (n = 16)Gestational weight gain in pregnancy (kg)a9.2 ± 5.6 Adequate (n,%)8 (50%) Inadequate2 (12.5%) Excessive6 (37.5%)Gestational age at delivery, median ± IQR37 weeks 6 days ±7 daysCongenital anomalies (n,%)0 (0%)Birthweight (grams)3535.6 ± 510 LGA (>99%)2 (12.5) LGA (95–99%)6 (37.5)HDP Gestational hypertension3 (18.8%) Preeclampsia3 (18.8%)Placental abruption0 (0%)PTD (iatrogenic)1 (6.3%)NICU admission4 (25%)Mode of delivery Spontaneous vaginal delivery5 (31.3%) Operative vaginal delivery1 (6.3%) Cesarean delivery10 (62.5%)LGA: large for gestational age.aClassification by Institute of Medicine criteria. Maternal and neonatal outcomes. LGA: large for gestational age. Classification by Institute of Medicine criteria. Following discontinuation of semaglutide, 62.5% were managed on a combination of insulin and metformin. The range of basal insulin required prior to delivery was 0–260 units. Preterm delivery occurred in one individual at 35 weeks 0 days, for uncontrolled diabetes mellitus and severe preeclampsia. All other individuals had iatrogenic delivery at term for T2DM. Secondary indications for timed delivery included: preeclampsia (3/16), large for gestational age (LGA, 3/16), chronic or gestational hypertension (3/16), obesity (2/16), polyhydramnios (1/16), and decreasing insulin requirements (1/16). Indications were not mutually exclusive. For the 10 individuals who delivered by Cesarian section (CS), the most common reason was previous CS (5/10). Other reasons included failed induction (2/10), abnormal fetal heart rate (1/10), LGA ≥4.5 kg (1/10), and patient request (1/10). Of the three individuals who experienced preeclampsia, all were multiparous, one had chronic hypertension, two were obese, and one was overweight. No major fetal anomalies were identified. There was one fetus with a thick nuchal fold; aneuploidy testing and chromosomal microarray were normal. There was no fetal growth restriction diagnosed. Polyhydramnios complicated one pregnancy. Discussion No major congenital malformations were observed in pregnancies inadvertently exposed to semaglutide during the periconceptual period and first trimester in this study. There was one instance of iatrogenic preterm birth at 35 weeks of gestation. This individual had induction of labour due to worsening preeclampsia. In a previous study reporting possible increased risk of preterm birth with GLP-1 RAs, it is unclear whether this was due to spontaneous preterm labour, or medically necessitated urgent delivery [1]. The median gestational age at delivery in this study was 37 weeks 6 days of gestation, which is slightly earlier than the recommended timing of delivery for individuals with pre-existing diabetes in Canada, that is, 38–39 weeks [11]. This may reflect the higher incidence of preeclampsia, which would prompt earlier delivery. The prevalence of preeclampsia in this series of patients (18.8%) is double the expected risk for individuals with T2DM (9.1%) [13]. This may be due to the higher rate of obesity (75%) in our series; however, not all individuals with preeclampsia were obese. Notably, the only other risk factor identified in the three patients developing preeclampsia was one patient with a history of chronic hypertension and previous preeclampsia. Given the high rate of obesity, there was a lower-than-expected rate of excessive GWG. In a previous study of T2DM, the rate of excessive GWG was 73.4%, compared with 37.5% in our study [13]. Conversely, a 2025 systematic review demonstrated that excessive GWG is associated with hypertensive disorders of pregnancy [14], which is inconsistent with the current findings of lower-than-expected excessive GWG, but higher rates of preeclampsia. Conclusions cannot be drawn based on comparison with previous studies, and further research is required to determine whether GLP-1 RA exposure influences preeclampsia risk via an effect on excessive GWG or diabetes control. This case series adds to the growing body of evidence regarding GLP-1 RA use in pregnancy. Because the data is extracted from patient charts rather than from population databases, detailed information about the course of pregnancy and maternal health can be reported. However, a weakness of the study is that some data were missing, such as miscarriage before 12 weeks, as booking in prenatal clinics are typically later. This is a small case series of patients who had been exposed to semaglutide in pregnancy, consistent with the fact that individuals are typically advised to avoid these medications for two months prior to conception. Despite the small sample size, additional primary data is valuable to the global literature, particularly when outcomes can be described in detail. While this study and the existing literature are reassuring, more studies on the safety of GLP-1 RAs in pregnancy are required. The possibility of optimizing perinatal outcomes with these medications could also be investigated. In this series of individuals inadvertently exposed to GLP-1 RAs in the first trimester, there were no major congenital anomalies identified. Rates of excessive gestational weight gain were lower than expected. Contributors Karen Wong contributed to conception of the case series, interpreting the data and drafting the manuscript. Houda Al-Amri contributed to conception of the case series, ethics submission, acquiring the data and revising the article critically for important intellectual content. Ana Werlang contributed to patient care, conception of the case series and revising the article critically for important intellectual content. All authors approved the final submitted manuscript. Patient consent As a retrospective case series using previously collected clinical data, informed consent was not sought or obtained. Ethical approval Institutional research ethics board approval was obtained from the Ottawa Health Science Network, REB #20240722-01H. Provenance and peer review This article was not commissioned and was peer reviewed. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Declaration of competing interest The authors declare that they have no competing interest regarding the publication of this case report. References